167 related articles for article (PubMed ID: 34712771)
21. Increased ratio of sST2/LVMI predicted cardiovascular mortality and heart failure rehospitalization in heart failure with reduced ejection fraction patients: a prospective cohort study.
Li F; Xu M; Fu M; Cui X; Lian Z; Xin H; Zhou J; Ge J
BMC Cardiovasc Disord; 2021 Aug; 21(1):396. PubMed ID: 34404341
[TBL] [Abstract][Full Text] [Related]
22. Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus.
Hammer F; Genser B; Dieplinger B; Egger M; Müller T; Drechsler C; März W; Störk S; Wanner C; Krane V
Clin Kidney J; 2022 Oct; 15(10):1915-1923. PubMed ID: 36158148
[TBL] [Abstract][Full Text] [Related]
23. Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis.
Lee YT; Gong M; Chau A; Wong WT; Bazoukis G; Wong SH; Lampropoulos K; Xia Y; Li G; Wong MCS; Liu T; Wu WKK; Tse G;
J Infect; 2018 Jan; 76(1):1-10. PubMed ID: 29174966
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis.
Zhang T; Xu C; Zhao R; Cao Z
Front Cardiovasc Med; 2021; 8():697837. PubMed ID: 34368254
[TBL] [Abstract][Full Text] [Related]
25. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure.
Mueller T; Dieplinger B; Gegenhuber A; Poelz W; Pacher R; Haltmayer M
Clin Chem; 2008 Apr; 54(4):752-6. PubMed ID: 18375488
[TBL] [Abstract][Full Text] [Related]
26. Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE).
Chen D; Untaru R; Stavropoulou G; Assadi-Khansari B; Kelly C; Croft AJ; Sugito S; Collins NJ; Sverdlov AL; Ngo DTM
J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109127
[TBL] [Abstract][Full Text] [Related]
27. Long-term prognostic importance of high levels of sST2 in patient with AMI: a meta-analysis.
Ji H; Yuan L; Jiang W; Chen J
Am J Transl Res; 2024; 16(1):1-11. PubMed ID: 38322566
[TBL] [Abstract][Full Text] [Related]
28. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension.
Zheng YG; Yang T; He JG; Chen G; Liu ZH; Xiong CM; Gu Q; Ni XH; Zhao ZH
Clin Cardiol; 2014 Jun; 37(6):365-70. PubMed ID: 25068163
[TBL] [Abstract][Full Text] [Related]
29. ST2 elevation in heart failure, predictive of a high early mortality.
Dalal JJ; Digrajkar A; Das B; Bansal M; Toomu A; Maisel AS
Indian Heart J; 2018; 70(6):822-827. PubMed ID: 30580851
[TBL] [Abstract][Full Text] [Related]
30. [Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation].
Skvortsov AA; Protasov VN; Narusov OY; Koshkina DE; Nasonova SN; Masenko VP; Tereschenko SN
Kardiologiia; 2017 Jan; (1):48-58. PubMed ID: 28290833
[TBL] [Abstract][Full Text] [Related]
31. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
[TBL] [Abstract][Full Text] [Related]
32. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
Emdin M; Aimo A; Vergaro G; Bayes-Genis A; Lupón J; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Gullestad L; Broch K; Ueland T; Nymo SH; Brunner-La Rocca HP; de Boer RA; Gaggin HK; Ripoli A; Passino C; Januzzi JL
J Am Coll Cardiol; 2018 Nov; 72(19):2309-2320. PubMed ID: 30384887
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure.
Tang WH; Wu Y; Grodin JL; Hsu AP; Hernandez AF; Butler J; Metra M; Voors AA; Felker GM; Troughton RW; Mills RM; McMurray JJ; Armstrong PW; O'Connor CM; Starling RC
JACC Heart Fail; 2016 Jan; 4(1):68-77. PubMed ID: 26656144
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus.
Li M; Duan L; Cai Y; Hao B; Chen J; Li H; Liu H
Cardiovasc Diabetol; 2021 Feb; 20(1):49. PubMed ID: 33608010
[TBL] [Abstract][Full Text] [Related]
35. Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure.
Jiang SW; Wang P; Xiang XG; Mo RD; Lin LY; Bao SS; Lu J; Xie Q
Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):181-188. PubMed ID: 28381383
[TBL] [Abstract][Full Text] [Related]
36. Increased Soluble Suppression of Tumorigenicity 2 Level Predicts All-Cause and Cardiovascular Mortality in Maintenance Hemodialysis Patients: A Prospective Cohort Study.
Zhang Z; Shen B; Cao X; Liu Z; Chen X; Nie Y; Yu J; Zou J; Ding X
Blood Purif; 2017; 43(1-3):37-45. PubMed ID: 27875808
[TBL] [Abstract][Full Text] [Related]
37. Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure-A Prospective Observational Study.
Dworok V; Hähnel V; Bannehr M; Paar V; Edlinger C; Lichtenauer M; Butter C; Haase-Fielitz A
J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068252
[TBL] [Abstract][Full Text] [Related]
38. Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction.
Huang WP; Zheng X; He L; Su X; Liu CW; Wu MX
Chin Med J (Engl); 2018 Jun; 131(11):1282-1288. PubMed ID: 29786039
[TBL] [Abstract][Full Text] [Related]
39. Serum Cardiac Biomarkers in Asymptomatic Hemodialysis Patients: Role of Soluble Suppression of Tumorigenicity-2.
Mancianti N; Maresca B; Palladino M; Salerno G; Cardelli P; Menè P; Barberi S
Blood Purif; 2022; 51(2):155-162. PubMed ID: 33910194
[TBL] [Abstract][Full Text] [Related]
40. The Prognostic Role of ST2L and sST2 in Patients Who Underwent Carotid Plaque Endarterectomy: A Five-Year Follow-Up Study.
Scicchitano P; Marzullo A; Santoro A; Zito A; Cortese F; Galeandro C; Ciccone AS; Angiletta D; Manca F; Pulli R; Navarese EP; Gurbel PA; Ciccone MM
J Clin Med; 2022 May; 11(11):. PubMed ID: 35683529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
